Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-11T06:23:47.497Z Has data issue: false hasContentIssue false

6 - Neurocritical Care Pharmacology

Published online by Cambridge University Press:  19 May 2022

By
Deepika P McConnell
Edited by
Andrew M. Naidech
Andrew M. Naidech
Affiliation:
Northwestern University, Illinois
Get access

Summary

Patients in the neurological ICU can be challenging to care for, and treatment often involves complex medication regimens. This chapter provides a quick and concise reference to medication therapies used in the neurocritical care population. The topics span general critical care, including vasopressors and sedatives, but also provide guidance on treatment of neurospecific disease states such as sodium disorders and paroxysmal sympathetic hyperactivity, where robust data do not exist.

Type
Chapter
Information
Neurocritical Care , pp. 111 - 133
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Torre-Healy, A, Marko, NF, Weil, RJ. Hyperosmolar therapy for intracranial hypertension. Neurocrit Care. 2012;17:117–30.CrossRefGoogle ScholarPubMed
Brophy, GM, Human, T. Pharmacotherapy pearls for emergency neurological life support. Neurocrit Care. 2017;27:51–73.CrossRefGoogle ScholarPubMed
Li, M, Chen, T, Chen, S, et al. Comparison of equimolar doses of mannitol and hypertonic saline for the treatment of elevated intracranial pressure after traumatic brain injury: a systematic review and meta-analysis. Medicine. 2015;94(17):e736.CrossRefGoogle Scholar
Jentzer, JC, Coons, JC, Link, CB, Schmidhofer, M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015;20(3):249–60.CrossRefGoogle ScholarPubMed
Bauer, SR, Sacha, GL, Lam, SW. Safe use of vasopressin and angiotensin II for patients with circulatory shock. Pharmacotherapy. 2018;38(8):851–61.CrossRefGoogle ScholarPubMed
Khanna, A, English, S, Wang, XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419–30.CrossRefGoogle ScholarPubMed
Rose, JC, Mayer, SA. Optimizing blood pressure in neurological emergencies. Neurocrit Care. 2004;1:287–99.CrossRefGoogle ScholarPubMed
Devlin, JW, Skrobik, Y, Gélinas, C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-73.CrossRefGoogle ScholarPubMed
Yahwak, JA, Riker, RR, Fraser, GL, Subak-Sharpe, S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy. 2008;28(8):984–91.CrossRefGoogle ScholarPubMed
Buffington, MA, Abreo, K. Hyponatremia: a review. Intensive Care Med. 2016;31(4):223–36.Google ScholarPubMed
Chester, KW, Rabinovich, M, Luepke, KH, et al. Sodium disorders in critically ill neurologic patients: a focus on pharmacologic management. OA Crit Care. 2014;2(1):2.Google Scholar
Murphy, T, Dhar, R, Diringer, M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009;11(1):14–19.CrossRefGoogle ScholarPubMed
Castonguay, AC, Jumaa, MA, Zaidat, OO, et al. Insights into intra-arterial thrombolysis in the modern era of mechanical thrombectomy. Front Neurol. 2019;10:1195.CrossRefGoogle ScholarPubMed
Dabus, G, Nogueira, RG. Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature. Interv Neurol. 2013;2(1):30–51.CrossRefGoogle ScholarPubMed
Ross, JC, Cook, AM, Stewart, GL, et al. Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care. 2011;14:103–08.CrossRefGoogle ScholarPubMed
Meythaler, JM, Roper, JF, Brunner, RC. Cypropheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil. 2003;84(5):638–42.CrossRefGoogle Scholar
Coffey, RJ, Edgar, TS, Francisco, GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83:735–41.CrossRefGoogle ScholarPubMed
Cohen, SP, Dragovich, A. Intrathecal analgesia. Anesthesiol Clin. 2007;25(4):863–82. Table 1, Conversion ratios between commonly used opioid agonists; p 865.CrossRefGoogle ScholarPubMed
LeBras, M, Chow, I, Mabasa, VH, et al. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular aminoglycosides in adults. Neurocrit Care. 2016;25(3):492–507.CrossRefGoogle ScholarPubMed
Ng, K, Mabasa, VH, Chow, I, et al. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. Neurocrit Care. 2014;20:158–71.CrossRefGoogle ScholarPubMed
Tunkel, AR, Hasbun, R, Bhimraj, A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):e34–65.Google Scholar
Kiser, TH. Cerebral vasospasm in critically ill patients with aneurysmal subarachnoid hemorrhage: does the evidence support the ever-growing list of potential pharmacotherapy interventions? Hosp Pharm. 2014;49:923–41.CrossRefGoogle Scholar
Rabinstein, AA, Benarroch, EE. Treatment of paroxysmal sympathetic hyperactivity. Curr Treat Options Neurol. 2008;10:151–57.CrossRefGoogle ScholarPubMed
Thomas, A, Greenwald, BD. Paroxysmal sympathetic hyperactivity and clinical considerations for patients with acquired brain injuries: a narrative review. Am J Phys Med Rehabil. 2019;98(1):65–72. Table 4, Pharmacologic options for the treatment of PSH; p 69.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×